EW
Edwards Lifesciences CorporationNYSEHealthcare$81.05-0.26%ClosedMarket Cap: $47.07B
As of 2026-04-06
Valuation
P/E (TTM)
43.99
PEG
—
P/B
4.55
P/S
7.76
EV/EBITDA
32.23
DCF Value
$61.65
FCF Yield
2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.1%
Operating Margin
26.7%
Net Margin
17.6%
ROE
10.4%
ROA
9.9%
ROIC
11.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.57B | 78.3% | $370.3M | $91.2M | $0.16 | — |
| FY 2025 | $6.07B | 78.1% | $1.64B | $1.07B | $1.83 | — |
| Q3 2025 | $1.55B | 77.9% | $425.1M | $291.1M | $0.50 | — |
| Q2 2025 | $1.53B | 77.6% | $430.9M | $329.8M | $0.56 | — |
| Q1 2025 | $1.41B | 78.7% | $394.8M | $358.0M | $0.61 | — |
| Q4 2024 | $1.39B | 78.9% | $312.6M | $385.6M | $0.65 | — |
| FY 2024 | $5.44B | 79.5% | $1.38B | $4.17B | $6.97 | — |
| Q3 2024 | $1.35B | 80.6% | $350.6M | $3.07B | $5.13 | — |
| Q2 2024 | $1.39B | 78.5% | $364.7M | $363.7M | $0.61 | — |
| Q1 2024 | $1.33B | 78.2% | $355.5M | $351.9M | $0.58 | — |
| Q4 2023 | $1.27B | 80.2% | $356.7M | $369.9M | $0.61 | — |
| FY 2023 | $5.01B | 79.3% | $1.43B | $1.40B | $2.30 | — |